CHINA PHARMA HOLDINGS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
2ND FLOOR, NO. 17, JINPAN ROAD, HAINAN PROVINCE, F4, 570216
Mailing Address
2ND FLOOR, NO. 17, JINPAN ROAD, HAINAN PROVINCE, F4, 570216
Phone
8689866811730
Fiscal Year End
1231
EIN
731564807
Financial Overview
FY2025
$8.26M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | April 1, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 8-K Current report of material events | February 10, 2026 | View on SEC |
| 8-K Current report of material events | January 6, 2026 | View on SEC |
| 8-K Current report of material events | December 23, 2025 | View on SEC |
| 8-K Current report of material events | December 10, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | May 14, 2025 | View on SEC |
Annual Reports
10-K
April 1, 2026
- Flagship heart medication Candesartan Cilexetil passed strict government quality tests, enabling direct competition in public hospitals.
- Strategic pivot toward Modern Traditional Chinese Medicine to capture growth in the aging population segment.
Material Events
8-K
Acquisition
March 3, 2026
High Impact
- CPHI expands drug pipeline with exclusive patent acquisition for "Prinsepia Utilis Esterol Sublingual Tablets."
- Acquisition strengthens the company's long-term product offerings and diversifies its drug portfolio.
8-K
Acquisition
February 10, 2026
High Impact
- Strategic expansion into the gout treatment market and intellectual property portfolio.
- Acquisition of patent rights for 'Topiroxostat Nanoemulsion' with inventor's technical support.
8-K
Strategy Change
January 6, 2026
High Impact
- Shareholders approved a reverse stock split of up to 1-for-20 shares for CHINA PHARMA HOLDINGS, INC.
- New independent directors (Gene Michael Bennett, Yingwen Zhang, and Baowen Dong) were elected to the Board.
8-K
Acquisition
December 10, 2025
High Impact
- China Pharma Holdings, Inc. acquired patent rights for a Captopril microcapsule through its wholly-owned subsidiary.
- The acquisition was paid for with $6.3 million worth of company stock, involving the issuance of 3.5 million new shares.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.